CCM
BMRN icon

Coldstream Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Coldstream Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Sell
5,077
-2,012
-28% -$110K ﹤0.01% 980
2026
Q1 		$400K Sell
7,089
-4,167
-37% -$243K ﹤0.01% 819
2025
Q4 		$669K Buy
11,256
+769
+7% +$41.9K 0.01% 595
2025
Q3 		$568K Buy
10,487
+4,428
+73% +$253K 0.01% 687
2025
Q2 		$333K Buy
6,059
+3,228
+114% +$190K 0.01% 832
2025
Q1 		$200K Buy
+2,831
New +$190K ﹤0.01% 1005

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Coldstream Capital Management's BMRN Position: Q2 2026 in Review

Coldstream Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 28% in Q2 2026, selling an estimated $110K and leaving 5,077 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Coldstream Capital Management first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $669K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Coldstream Capital Management held 5,077 shares of BioMarin Pharmaceuticals worth $291K as of Q2 2026.
  • Coldstream Capital Management sold 2,012 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $110K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #980 holding.
  • Coldstream Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Coldstream Capital Management's BioMarin Pharmaceuticals position peaked at $669K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.